Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia ...Middle East

ROCKVILLE, Md. and SUZHOU, China, Aug. 16, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic,...

Hence then, the article about innovent announces the nmpa approval of sintbilo tafolecimab injection for the treatment of adult patients with primary hypercholesterolemia and mixed dyslipidemia was published today ( Thursday 17/08/2023 - 03:09 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia )

Also on site :

• Inside the chaos at Canoo, the zero-revenue, cash-burning EV company that just inked a major deal with Walmart
• Zelensky’s inner circle accused of war profiteering
• ServiceNow just unveiled an AI workforce that can run your entire company: ‘Enterprises need AI that senses, decides, and securely acts’